Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- FHTX
- Price
- 3.45
- Stock movement up
- +0.22 (6.81%)
- Company name
- Foghorn Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 191.80M
- Ent value
- 470.78M
- Price/Sales
- 7.52
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -52.48%
- 3 year return
- -40.68%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
FHTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.52 |
| Price to Book | - |
| EV to Sales | 18.45 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 55.59M |
| EPS (TTM) | -1.46 |
| FCF per share (TTM) | -1.66 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 25.52M |
| Gross profit (TTM) | 22.33M |
| Operating income (TTM) | -101.74M |
| Net income (TTM) | -91.22M |
| EPS (TTM) | -1.46 |
| EPS (1y forward) | -1.35 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 87.51% |
| Operating margin (TTM) | -398.74% |
| Profit margin (TTM) | -357.53% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 57.68M |
| Net receivables | 0.00 |
| Total current assets | 271.23M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 308.37M |
| Accounts payable | 3.45M |
| Short/Current long term debt | 39.07M |
| Total current liabilities | 56.82M |
| Total liabilities | 336.66M |
| Shareholder's equity | -28.29M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -103.43M |
| Capital expenditures (TTM) | 464.00K |
| Free cash flow (TTM) | -103.89M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -29.58% |
| Return on Invested Capital | 848.82% |
| Cash Return on Invested Capital | 966.71% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.26 |
| Daily high | 3.48 |
| Daily low | 3.14 |
| Daily Volume | 70K |
| All-time high | 25.88 |
| 1y analyst estimate | 16.00 |
| Beta | 3.15 |
| EPS (TTM) | -1.46 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 May 2025 |
Downside potential
Loading...
Downside potential data
| FHTX | S&P500 | |
| Current price drop from All-time high | -86.67% | -12.89% |
| Highest price drop | -89.10% | -56.47% |
| Date of highest drop | 5 Feb 2024 | 9 Mar 2009 |
| Avg drop from high | -62.28% | -11.07% |
| Avg time to new high | 140 days | 12 days |
| Max time to new high | 1083 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
191.80M
Marketcap category
Small-cap
Description
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Employees
116
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page